TD Private Client Wealth’s BridgeBio Pharma BBIO Stock Holding History

TD Private Client Wealth’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2	Closed	-$153	–	1659
2025 Q4	$153	Buy	+2	New	+$131	﹤0.01%	1567
2025 Q2	–	Sell	-31	Closed	-$1.07K	–	1419
2025 Q1	$1.07K	Buy	+31	New	+$1.04K	﹤0.01%	1283

Other funds holding BBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TD Private Client Wealth's BBIO Position: Q1 2026 in Review

TD Private Client Wealth sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 2 shares — an estimated $153 sold.

TD Private Client Wealth first reported a position in BBIO in Q1 2025 and held it in 2 quarters. The position peaked at $1.07K in Q1 2025. 460 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

TD Private Client Wealth reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
TD Private Client Wealth sold 2 BridgeBio Pharma shares in Q1 2026, an estimated $153.
TD Private Client Wealth first reported a position in BridgeBio Pharma in Q1 2025 and held it in 2 quarters.
TD Private Client Wealth's BridgeBio Pharma position peaked at $1.07K in Q1 2025.
460 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on TD Private Client Wealth's 13F filing for Q1 2026, filed 27 Apr 2026.